The FDA on June 26 granted Boehringer Ingelheim and Eli Lilly and Company’s drug empagliflozin Fast Track designation for the treatment of chronic heart failure, the companies announced.

One in five Americans are able to recognize the symptoms of heart failure, according to a new survey from Abbott—a troublesome finding considering the same research puts the average individual just four degrees of separation from HF.

Researchers at Imperial College London have developed a sew-on heart patch that leverages stem cells to support and repair heart muscle after a heart attack—something that could dramatically lower MI survivors’ risk of future heart failure.

Loneliness, above all else, was an independent predictor of whether patients stuck to their doctors’ guidelines.

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

The risk of peripartum cardiomyopathy (PPCM) is up to five times higher in mothers who undergo common fertility treatments like intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), according to data presented at Heart Failure 2019 in Athens.

Results from the FDA’s latest investigation into Abiomed’s Impella RP system are in—and, with a couple of caveats, they’re positive.

A six-week online training course centered around living with an implantable cardioverter-defibrillator (ICD) helped alleviate anxiety in heart failure patients who were apprehensive about their devices.